Pancreatic cancer belongs to the incurable family of solid cancers. Despite of a recent better
understanding its molecular biology, and an increased number of clinical trials, there is still a
lack for innovative targeted therapies to fight this deadly malignancy. PI3K/Akt signalling is
one of the most commonly deregulated signalling pathways in cancer, which explains the
massive attention from many pharmaceutical companies over the ten past years on these
signalling molecules. The already developed small molecule inhibitors are currently under …